

Mometasone Dry Powder Inhaler Formulation

Version 4.0 Revision Date: 06.04.2024 SDS Number: 437333-00019 Date of last issue: 30.09.2023
Date of first issue: 28.01.2016

Section 1: Identification

Product identifier : Mometasone Dry Powder Inhaler Formulation

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable


Manufacturer or supplier's details

Company : Organon & Co.
Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : +1-551-430-6000
Emergency telephone number : +1-215-631-6999
E-mail address : EHSSTEWARD@organon.com

Section 2: Hazard identification**Classification of the substance or mixture**

Reproductive toxicity : Category 1B
Specific target organ toxicity - repeated exposure (Inhalation) : Category 2 (Immune system, Liver, Kidney, Skin)
Long-term (chronic) aquatic hazard : Category 1

GHS Label elements, including precautionary statements

Hazard pictograms : 

Signal word : Danger

Hazard statements : H360Df May damage the unborn child. Suspected of damaging fertility.
H373 May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.
H410 Very toxic to aquatic life with long lasting effects.

Mometasone Dry Powder Inhaler Formulation

Version 4.0 Revision Date: 06.04.2024 SDS Number: 437333-00019 Date of last issue: 30.09.2023
Date of first issue: 28.01.2016

Precautionary statements

Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Mometasone	83919-23-7	>= 10 -< 20

Section 4: First-aid measures**Description of necessary first-aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

If swallowed : Get medical attention if irritation develops and persists.
 : If swallowed, DO NOT induce vomiting.
 : Get medical attention.
 : Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed

Risks : May damage the unborn child. Suspected of damaging fertility.
 : May cause damage to organs through prolonged or repeated exposure if inhaled.
 : Contact with dust can cause mechanical irritation or drying of the skin.
 : Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures**Extinguishing media**

Suitable extinguishing media : Water spray
 : Alcohol-resistant foam
 : Carbon dioxide (CO₂)
 : Dry chemical

Unsuitable extinguishing media : None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
 : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
 : Chlorine compounds

Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
 : Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
 : Use water spray to cool unopened containers.
 : Remove undamaged containers from fire area if it is safe to do so.
 : Evacuate area.

Section 6: Accidental release measures**Personal precautions, protective equipment and emergency procedures**

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage**Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage, including any incompatibilities

- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

- Appropriate engineering control measures** : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.

Individual protection measures, such as personal protective equipment (PPE)

- Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

posable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Section 9: Physical and chemical properties

Appearance : powder

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Mometasone Dry Powder Inhaler Formulation

Version 4.0 Revision Date: 06.04.2024 SDS Number: 437333-00019 Date of last issue: 30.09.2023
Date of first issue: 28.01.2016

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics
Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Mometasone:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

	LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 3.3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.
	LC50 (Mouse): > 3.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute toxicity (other routes of administration)	: LD50 (Rat): 300 mg/kg Application Route: Subcutaneous Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Components:**Mometasone:**

Species	: Rabbit
Result	: No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Mometasone:**

Species	: Rabbit
Result	: No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Mometasone:**

Test Type	: Maximisation Test
Exposure routes	: Dermal
Species	: Guinea pig
Assessment	: Does not cause skin sensitisation.
Result	: negative
Remarks	: The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Mometasone Dry Powder Inhaler Formulation

Version
4.0Revision Date:
06.04.2024SDS Number:
437333-00019Date of last issue: 30.09.2023
Date of first issue: 28.01.2016**Germ cell mutagenicity**

Not classified based on available information.

Components:**Mometasone:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Chinese hamster lung cells Result: negative
		Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: positive
		Test Type: Mouse Lymphoma Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative
		Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Mometasone:**

Species	:	Rat
Application Route	:	Inhalation
Exposure time	:	2 Years
Dose	:	0.067 mg/kg body weight
Result	:	negative
Species	:	Mouse
Application Route	:	Inhalation

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

Exposure time	:	19 Months
Dose	:	0.160 mg/kg body weight
Result	:	negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:**Mometasone:**

Effects on fertility	:	Test Type: Fertility
		Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0.015 mg/kg body weight Symptoms: Reduced embryonic survival, Reduced foetal weight Result: No effects on fertility, Effect on reproduction capacity
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Mouse Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmental toxicity
		Test Type: Embryo-foetal development Species: Rat Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight Result: Embryo-foetal toxicity
		Test Type: Embryo-foetal development Species: Rabbit Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.
		Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Effects on newborn
		Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.
Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

||

STOT - single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks	:	Based on available data, the classification criteria are not met.
---------	---	---

STOT - repeated exposure

May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

Components:**Mometasone:**

Exposure routes	:	inhalation (dust/mist/fume)
Target Organs	:	Immune system, Liver, Kidney, Skin
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Mometasone:**

Species	:	Rat
NOAEL	:	0.005 mg/kg
LOAEL	:	0.3 mg/kg
Application Route	:	Oral
Exposure time	:	30 d
Target Organs	:	Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	:	Dog
NOAEL	:	0.5 mg/kg
Application Route	:	Oral
Exposure time	:	30 d
Target Organs	:	Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	:	Rat
NOAEL	:	0.00013 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species	:	Dog
NOAEL	:	0.0005 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Mometasone Dry Powder Inhaler Formulation

Version 4.0	Revision Date: 06.04.2024	SDS Number: 437333-00019	Date of last issue: 30.09.2023 Date of first issue: 28.01.2016
----------------	------------------------------	-----------------------------	---

|| Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:**Mometasone:**

|| Not applicable

Experience with human exposure**Components:****Mometasone:**

Inhalation	: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	: Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

|| Remarks : Dermal absorption possible

Section 12: Ecological information
Toxicity**Components:****Mometasone:**

Toxicity to fish	: LC50 (Menidia beryllina (Silverside)): 0.11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility
	LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
	EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.34 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
M-Factor (Chronic aquatic toxicity)	:	100
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
		NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility

Persistence and degradability**Components:****Mometasone:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	:	Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111

Bioaccumulative potential**Components:****Mometasone:**

Bioaccumulation	:	Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305
-----------------	---	--

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

Partition coefficient: n-octanol/water : log Pow: 4.68

Mobility in soil**Components:****Mometasone:**

Distribution among environmental compartments : log Koc: 4.02

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer. Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number : UN 3077

UN proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)

Transport hazard class(es) : 9

Packing group : III

Labels : 9

Environmental hazards : yes

IATA-DGR

UN/ID No. : UN 3077

UN proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Mometasone)

Transport hazard class(es) : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 956

Packing instruction (passenger aircraft) : 956

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
4.0	06.04.2024	437333-00019	30.09.2023
			Date of first issue: 28.01.2016

N.O.S.
(Mometasone)

Transport hazard class(es)	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Section 15: Regulatory information**Safety, health and environmental regulations specific for the product in question**

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations	: Not applicable
---	------------------

Fire Safety (Petroleum and Flammable Materials) Regulations	: Not applicable
---	------------------

The components of this product are reported in the following inventories:

AICS	: not determined
------	------------------

DSL	: not determined
-----	------------------

IECSC	: not determined
-------	------------------

Section 16: Other information

Revision Date	: 06.04.2024
---------------	--------------

Further information

Sources of key data used to compile the Safety Data Sheet	: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
---	---

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format	: dd.mm.yyyy
-------------	--------------

Mometasone Dry Powder Inhaler Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	06.04.2024	437333-00019	Date of first issue: 28.01.2016

Full text of other abbreviations

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN